A Phase 2, Single-Arm Study To Assess The Efficacy and Safety Of 72-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Once Every 2 Weeks in Myelodysplastic Syndrome Patients With Trisomy 8 or Classified as Intermediate-1, 2 or High Risk

Trial Profile

A Phase 2, Single-Arm Study To Assess The Efficacy and Safety Of 72-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Once Every 2 Weeks in Myelodysplastic Syndrome Patients With Trisomy 8 or Classified as Intermediate-1, 2 or High Risk

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Rigosertib (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Onconova Therapeutics
  • Most Recent Events

    • 29 Jun 2017 NCT01326377 is an obsolete identifier of NCT00906334
    • 26 Feb 2014 The dosing regimen has been changed; primary endpoint 'number of patients with adverse events' has been added.
    • 26 Feb 2014 The dosing regimen has been changed; primary endpoint 'number of patients with adverse events' has been added.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top